Talia Emery
Burbank, CANPI 1376632844
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $84,486 of the $92,424 with a category attached, or 91.4%. AbbVie accounts for 98.1% of it on its own, with 3 other manufacturers making up the rest.
Across 218 payments — averaging $423.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$91K
- Merz North America, Inc.$1K
- Galderma Laboratories, L.p.$436
- Revance Therapeutics, Inc.$17
What the payments were for
- Speaking & faculty fees$84,48691%
- Travel & lodging$2,4453%
- Food & beverage$5,4936%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 170 | $90,649 |
| Merz North America, Inc. | 24 | $1,322 |
| Galderma Laboratories, L.p. | 23 | $436 |
| Revance Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$33,712
- BOTOX COSMETIC$1,000
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.